Brepocitinib, a selective JAK-1 and TYK-2 inhibitor (Figure 3b), was able to achieve statistically significant reductions from baseline in EASI total score at week 6 compared with their respective vehicles in 292 adolescent (>12 years old) and adult participants with mild to moderate AD at week 6 versus the vehicle treatment in a phase 2b double-blind, dose-ranging study by Landis et al. [188]. Here, TYK2 is linked to Alzheimer disease.